Theravance Biopharma (TBPH) Capital Expenditures (2013 - 2025)
Theravance Biopharma's (TBPH) quarterly Capital Expenditures came in at $8000.0 in Q4 2025, down 95.79% year-on-year from $190000.0 in Q4 2024, and down 95.79% on a QoQ basis from $190000.0 in Q4 2024.
Theravance Biopharma (TBPH) Capital Expenditures (2013 - 2025) Analysis & Trends
Theravance Biopharma (TBPH) has 13 years of Capital Expenditures data on file, last reported at $8000.0 in Q4 2025.
- On a quarterly basis, Capital Expenditures fell 95.79% year-over-year to $8000.0 in Q4 2025; TTM through Dec 2025 was $213000.0, a 35.84% decrease from a year earlier, with the FY2025 full-year figure at $42000.0, down 87.35% from the prior year.
- Capital Expenditures for Q4 2025 stood at $8000.0, down from $190000.0 in the prior quarter.
- Over the last five years, Capital Expenditures for TBPH reached as high as $1.8 million in Q1 2021 and fell as low as -$57000.0 in Q3 2022.
- Historically, Capital Expenditures has averaged $400352.9 across 5 years, with a median of $190000.0 in 2024.
- Across the five-year window, Capital Expenditures slumped 105.49% in 2022 and soared 653.98% in 2023, its largest moves.
- Year by year, Capital Expenditures stood at $444000.0 in 2021, then sank by 40.09% to $266000.0 in 2022, then surged by 154.51% to $677000.0 in 2023, then tumbled by 71.94% to $190000.0 in 2024, then tumbled by 95.79% to $8000.0 in 2025.
- Per Business Quant data, the three most recent Capital Expenditures figures were $8000.0 in Q4 2025, $190000.0 in Q4 2024, and $15000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Theravance Biopharma | 864.56 Mn | 469.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8,000.00 |
| Dec 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 190,000.00 |
| Dec 31, 2024 | 190,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 36,000.00 |
| Jun 30, 2024 | 36,000.00 |
| Mar 31, 2024 | 91,000.00 |
| Mar 31, 2024 | 91,000.00 |
| Dec 31, 2023 | 677,000.00 |
| Dec 31, 2023 | 677,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Jun 30, 2023 | 852,000.00 |
| Jun 30, 2023 | 852,000.00 |
| Mar 31, 2023 | 938,000.00 |
| Mar 31, 2023 | 938,000.00 |
| Dec 31, 2022 | 266,000.00 |
| Dec 31, 2022 | 266,000.00 |